It is possible that the lack of difference in efficacy between VR-CAP and RCHOP therapies is because NF-κB activity only serves as a prognostic factor for the high risk non-GCB subtype of DLBCL (B-IPI scores ≥4), which was observed in our study. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.